

**PATENT AGENT**

Portland Office  
503.473.0949  
stephen.burgess@klarquist.com

**EDUCATION**

Ph.D., Chemistry, Portland State University, 2008

B.Sc. (Hons) in Chemistry,  
University of Bristol, U.K., 1992

**ADMISSIONS**

U.S. Patent and Trademark Office,  
2013 (Reg. No. 71,428)

**PRACTICE AREAS**

Patents

**Technologies**

Chemical

Electrical & Semiconductors

Nanotechnology

## Stephen J. Burgess Ph.D.

Steven prepares and prosecutes U.S. patent applications and assists with the preparation and prosecution of international and foreign patent applications.

Steven is a patent agent skilled in all aspects of chemistry. He has more than 15 years of industrial experience in synthetic organic and medicinal chemistry, and also has experience in areas including nanoparticles, thin films and coatings, and semiconductors. Prior to joining Klarquist, Steven worked at a drug discovery company, designing and synthesizing novel antimalarial and antibacterial drugs. He also previously worked at a chemical company designing libraries for high-throughput screening, and synthesizing heterocyclic building blocks for drug discovery and pharmaceutical customers.

Steven joined Klarquist as a patent agent in 2013.

**Professional Experience**

- DesignMedix  
Portland, Oregon  
Senior Scientist, 2008 – 2013  
Designed and synthesized novel antimalarial and antibacterial drugs. Project manager for the preclinical testing of the lead RCQ candidate.
- Portland State University  
Portland, Oregon  
Research/Teaching Assistant, 2003 – 2008  
Dissertation title: Design and synthesis of antimalarial drugs based on a chloroquine scaffold.
- Maybridge Chemical Company  
Tintagel, Cornwall, England  
Scientist, 2001 – 2003  
Team Leader, 1999 – 2001  
Senior Chemist, 1995 – 1999  
Chemist, 1992 – 1995  
Designed and synthesized screening libraries, and synthetic intermediates, and managed custom synthesis projects.

**Professional Activities**

- Reviewer, Journal of Medicinal Chemistry

**Honors & Awards**

- Paul Emmett Outstanding Graduate Student Award, 2007

**Klarquist**

## Presentations & Publications

- Gunsaru B, Burgess SJ, Morrill W, Kelly JX, Shomloo S, Smilkstein MJ, Liebman K, Peyton DH. 2017. Simplified reversed chloroquinones to overcome malaria resistance to quinoline-based drugs. *Antimicrob Agents Chemother* 61:e01913-16
- Wirjanata G, Sebayang BF, Chalfein F, Prayoga, Handayuni I, Noviyanti R, Kenangalem E, Poespoprodjo JR, Burgess SJ, Peyton DH, Price RN, Marfurt J. 2015. Contrasting ex vivo efficacies of “reversed chloroquine” compounds in chloroquine-resistant *Plasmodium falciparum* and *P. vivax* isolates. *Antimicrob Agents Chemother* 59:5721–5726
- Burgess, SJ; Kelly, JX; Shomloo, S; Wittlin, S; Brun, R; Liebmann, K; Peyton, DH: Synthesis, Structure-Activity Relationship, and Mode-of-Action Studies of Antimalarial Reversed Chloroquine Compounds. *J. Med. Chem.* 2010, 53(17): 6477-6489
- Andrews S, Burgess SJ, Skaalrud D, Kelly JX, Peyton DH: Reversal agent and linker variants of reversed chloroquinones: activities against *Plasmodium falciparum*. *J. Med. Chem.* 2010, 53(2):916-919
- Burgess SJ, Selzer A, Kelly JX, Smilkstein MJ, Riscoe MK, Peyton DH: A Chloroquine-like Molecule Designed to Reverse Resistance in *Plasmodium falciparum*. *J. Med. Chem.* 2006, 49(18):5623-5625